The U.S. biosimilars market is a fast approaching reality. However, much uncertainty lies ahead, including the market potential as a function of physician adoption of biosimilars. This panel discussion was conducted to preview the thoughts and expectations of specialty physicians who would be expected to be among the first customers of biosimilars, with the objective of gaining insight into some of the major factors which could influence market uptake. The research for this service was gathered from a panel consisting of 20 pre-selected specialty physicians and was conducted via online moderated discussion boards over a three-day period. Key findings, qualitative analyses and recommendations are included.